Illustration: Tiffany Herring/Axios
Aktis Oncology, a biotech developing targeted radiopharmaceuticals for solid cancer tumors, set terms on its IPO, seeking to raise $212 million.
Why it matters: It's poised to be the first biotech to test the public markets this year.
